Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio

 
• By Jung Won Shin
liver
Yuhan Inks Second NASH License-Out Agreement • Source: Shutterstock

More from South Korea

More from Focus On Asia